The Evolving Landscape of Transplant Compatibility: Beyond the Blood Sample
For decades, a simple blood draw has been the cornerstone of human leukocyte antigen (HLA) typing – a critical step before hematopoietic stem cell transplantation (HSCT). But as transplant techniques advance, particularly haploidentical HSCT (haplo-HSCT) where donors are only a partial match, a more nuanced understanding of HLA genetics across different tissues is emerging. Recent research highlights the limitations of relying solely on peripheral blood for post-transplant HLA assessment, opening doors to more precise monitoring and improved patient outcomes.
The Challenge of Relapse and HLA Loss
HSCT offers a lifeline for many battling leukemia and other blood cancers. However, relapse remains a significant threat. A key factor in relapse is often the loss of heterozygosity (LOH) – a change in the HLA genetic makeup of leukemic cells, allowing them to evade the donor’s immune response. Traditionally, monitoring for this involved analyzing blood samples. But what happens when the blood reflects the donor’s HLA profile, masking potential changes in the recipient’s original genetic signature?
Here’s where the complexity arises. After haplo-HSCT, the recipient’s blood typically adopts the donor’s HLA genotype. Identifying HLA loss or changes in the recipient’s tissues then requires looking beyond the bloodstream. A recent study, published in February 2026, investigated HLA genotypes in peripheral blood, buccal swabs, and saliva samples from 66 patients post-haplo-HSCT, comparing them to pre-transplant profiles.
Beyond Blood: The Promise of Buccal Swabs and Saliva
The findings were revealing. While peripheral blood predominantly showed the donor’s HLA genotype, buccal swabs largely retained the patient’s pre-HSCT genetic makeup. Saliva samples presented a mixed picture, exhibiting both donor and recipient genotypes. This suggests that buccal cells, sourced from the lining of the cheek, offer a more stable representation of the patient’s original HLA profile post-transplant.
Pro Tip: For patients undergoing a second HSCT after a previous haplo-HSCT, clinicians should prioritize buccal swab sampling for HLA typing to accurately assess potential HLA loss and guide donor selection.
Interestingly, the study also uncovered instances of chimerism – the presence of both donor and recipient cells – and even complete donor HLA genotype replacement in a single patient’s buccal sample. These rare occurrences underscore the dynamic interplay between donor and recipient genetics post-transplant and highlight the need for comprehensive tissue-based analysis.
Uncovering Chimerism and Unexpected Genetic Shifts
The research detailed one case where a patient’s buccal swab displayed 11% chimerism of donor-specific HLA genes. This suggests that donor-derived stem cells may, in some instances, migrate and differentiate into epithelial cells within the oral mucosa. Even more remarkably, one patient exhibited a complete switch to the donor’s HLA genotype in their buccal swab, a finding that warrants further investigation to understand the underlying mechanisms.
Did you know? The cellular composition of saliva and buccal swabs differs significantly. Saliva contains a mix of epithelial and immune cells, while buccal swabs are primarily composed of epithelial cells, potentially explaining the varying HLA profiles observed in these samples.
Future Trends: Precision Monitoring and Personalized Transplantation
These findings are driving several key trends in the field of HSCT:
- Multi-Tissue HLA Genotyping: Moving beyond single-sample analysis to incorporate buccal swabs and saliva alongside peripheral blood for a more complete picture of HLA genetics.
- Advanced Sequencing Technologies: Utilizing next-generation sequencing (NGS) to detect subtle changes in HLA genotypes and identify LOH with greater accuracy.
- Minimal Residual Disease (MRD) Monitoring: Integrating HLA loss assessment with MRD detection to proactively identify patients at risk of relapse.
- Improved Donor Selection: Leveraging comprehensive HLA typing data to identify donors with haplotypes that minimize the risk of HLA loss and maximize long-term engraftment.
FAQ
Q: Why is HLA matching important in HSCT?
A: HLA molecules play a crucial role in the immune system. Mismatches can trigger immune responses that lead to graft rejection or graft-versus-host disease.
Q: What is LOH and why is it concerning?
A: LOH, or loss of heterozygosity, occurs when a gene is lost or altered, potentially allowing cancer cells to evade the immune system and cause relapse.
Q: Is buccal swab sampling now standard practice after HSCT?
A: While not yet universally standard, the growing body of evidence supports its inclusion, particularly when evaluating patients for a second transplant.
Q: What is chimerism?
A: Chimerism is the state of having a mixture of cells from two or more genetically distinct individuals.
The future of HSCT lies in precision medicine – tailoring treatment strategies to the individual patient’s genetic profile. By embracing a more comprehensive approach to HLA typing, incorporating insights from multiple tissues, and leveraging advanced technologies, we can move closer to achieving durable remissions and improving the lives of those battling hematologic malignancies.
Explore further: Read the full research article on HLA genotyping after haplo-HSCT.
